Publications by authors named "Ida N Hilmi"

Clinical guidelines typically endorse conventional therapies such as 5-aminosalicylic acid (5-ASA) as the mainstay of ulcerative colitis management. However, the degree of adoption and application of guideline recommendations by physicians within Asia remains unclear. This study aims to understand the prescribing patterns of 5-ASA and implementation of current guideline recommendations across Asian clinical practice.

View Article and Find Full Text PDF

Background: Older patients with constipation are at higher risk for inadequate bowel preparation, but there are currently no targeted strategies. This study aims to develop an abdominal vibration combined with walking exercise (AVCWE) program and assess its feasibility among older patients with constipation.

Methods: Phase I: Using the Delphi technique, eight experts across three professional fields were consulted to develop the AVCWE program.

View Article and Find Full Text PDF

Endoscopic ultrasonography-guided transesophageal pericardiocentesis was performed for a posteriorly located effusion not amenable to transthoracic drainage in a 58-year-old woman with a history of recurrent breast adenocarcinoma who presented with dyspnea. The patient had a pericardial effusion that resulted in cardiac tamponade. Transthoracic pericardiocentesis was unsuitable because of the posterior location of the effusion.

View Article and Find Full Text PDF

This systematic review aims to evaluate (1) the effectiveness of exercise therapy in bowel preparation for colonoscopy, and (2) the characteristics of exercise programs for bowel preparation. Systematic searches were done in PubMed, EMBASE, the Cochrane Library, Web of Science, and CINAHL from inception to November 2022. Randomized controlled trials and quasi-experimental studies assessing the efficacy of exercise during bowel preparation were included in this review.

View Article and Find Full Text PDF

Background: The differentiation between intestinal tuberculosis (ITB) and Crohn's disease (CD) remains a challenge, particularly in areas where tuberculosis is highly prevalent. Previous studies have identified features that favour one diagnosis over the other. The aim of the study was to determine the accuracy of a standardized protocol in the initial diagnosis of CD versus ITB.

View Article and Find Full Text PDF

Background: Pain is a contributing factor to the low compliance rate for performing a colonoscopy on screening for colorectal cancer.

Purpose: This meta-analysis aimed to evaluate the effect of visual distraction on adults undergoing colonoscopy.

Methods: We searched PubMed, EMBASE, Web of Science, and Cochrane Library Database from their inception to February 2022.

View Article and Find Full Text PDF

Background And Aims: Thiopurines, which are immunosuppressive drugs for maintaining remission for inflammatory bowel disease, are known to cause myelotoxicity in patients with Nudix Hydroxylase 15 () genetic variants in some Asian countries with monoethnic populations. We aimed to investigate the association of variants with leukopenia in a multiethnic population in Southeast Asia.

Methods: Patients with a confirmed diagnosis of inflammatory bowel disease were recruited.

View Article and Find Full Text PDF

Background And Aim: The spectrum of gastrointestinal (GI) and liver diseases is recognized to have a geographical variation, which may be due to environmental or genetic differences. We aimed to explore this further in a specialist clinic serving a multi-ethnic Asian urban population.

Methods: A retrospective analysis of outpatient data from this institution's electronic medical records was conducted between January and June 2019.

View Article and Find Full Text PDF

Objective: Converging evidence suggests that intestinal inflammation is involved in the pathogenesis of neurodegenerative diseases. Previous studies on fecal calprotectin in Parkinson's disease (PD) were limited by small sample sizes, and literature regarding intestinal inflammation in multiple system atrophy (MSA) is very scarce. We investigated the levels of fecal calprotectin, a marker of intestinal inflammation, in PD and MSA.

View Article and Find Full Text PDF

Background/aims: The efficacy and safety of vedolizumab in moderate-to-severely active Crohn's disease (CD) were demonstrated in the GEMINI 2 study (NCT00783692). This post-hoc exploratory analysis aimed to assess the efficacy and safety of vedolizumab in the subgroup of patients from Asian countries.

Methods: During the induction phase (doses at day 1, 15), clinical remission, enhanced clinical response, and change in C-reactive protein at 6 weeks; during the maintenance phase, clinical remission, enhanced clinical response, glucocorticoid-free remission and durable clinical remission at 52 weeks, were the efficacy outcomes of interest.

View Article and Find Full Text PDF

Background/aims: The efficacy and safety of vedolizumab in moderate to severely active ulcerative colitis (UC) have been demonstrated in the GEMINI 1 study (NCT00783718). This post-hoc exploratory analysis sought to establish the efficacy and safety of vedolizumab in a subgroup of patients from Asian countries with UC from GEMINI 1.

Methods: Efficacy outcomes of interest were clinical response, clinical remission and mucosal healing at week 6 (induction phase); and clinical remission, durable clinical response, durable clinical remission, mucosal healing and glucocorticoid-free remission at week 52 (maintenance phase).

View Article and Find Full Text PDF

Inflammatory bowel disease (IBD) has increased in incidence and prevalence in Asian countries since the end of the 20th century. Moreover, differences in the cause, phenotypes, and natural history of IBD between the East and West have been recognized. Therefore, the Asian Organization for Crohn's and Colitis and the Asia Pacific Association of Gastroenterology have established recommendations on medical management of IBD in Asia.

View Article and Find Full Text PDF

Background: Alteration in the natural history of Crohn's disease (CD) since the advent of biologic therapy remains to be proven. Our aim was to look at the intestinal surgical rates and the association with biologic therapy over the last two decades.

Methods: This was a retrospective study in which all CD patients seen in two tertiary referral hospitals in Malaysia were recruited.

View Article and Find Full Text PDF

Background: Swallow or deglutition syncope is an unusual type of neurally-mediated syncope associated with life-threatening bradyarrhythmia and hypotension. It is a difficult condition to diagnose with commonly delayed diagnosis and management. There is lack of review articles that elucidate the basic demographics, clinical characteristics and management of this rare condition.

View Article and Find Full Text PDF
Article Synopsis
  • Vedolizumab (ENTYVIO) is a medication used to treat inflammatory bowel disease by blocking specific immune cell trafficking to the gut, and it's important to evaluate the risk of opportunistic infections in patients taking it.
  • In clinical trials and post-marketing data, the annual incidence of opportunistic infections was low, at approximately 0.7 to 1.0 per 100 patient-years, with Clostridium difficile being the most common.
  • Interestingly, tuberculosis occurrences were rare, with no related deaths reported, and patients with histories of hepatitis B/C did not experience viral reactivation while on vedolizumab.
View Article and Find Full Text PDF

The concept of consuming microorganisms in the treatment of a medical condition and in health maintenance has gained much attraction, giving rise to an abundance of medical claims and of health supplements. This study identified relevant clinical questions on the therapeutic use of probiotics and reviewed the literature in irritable bowel syndrome, inflammatory bowel disease, impaired intestinal immunity, liver disease, intestinal infections, and common childhood digestive disorders. Statements were developed to address these clinical questions.

View Article and Find Full Text PDF

Because anti-tumor necrosis factor (anti-TNF) therapy has become increasingly popular in many Asian countries, the risk of developing active tuberculosis (TB) among anti-TNF users may raise serious health problems in this region. Thus, the Asian Organization for Crohn's and Colitis and the Asia Pacific Association of Gastroenterology have developed a set of consensus statements about risk assessment, detection and prevention of latent TB infection, and management of active TB infection in patients with inflammatory bowel disease (IBD) receiving anti-TNF treatment. Twenty-three consensus statements were initially drafted and then discussed by the committee members.

View Article and Find Full Text PDF

Because anti-tumor necrosis factor (anti-TNF) therapy has become increasingly popular in many Asian countries, the risk of developing active tuberculosis (TB) among anti-TNF users may raise serious health problems in this region. Thus, the Asian Organization for Crohn's and Colitis and the Asia Pacific Association of Gastroenterology have developed a set of consensus statements about risk assessment, detection and prevention of latent TB infection, and management of active TB infection in patients with inflammatory bowel disease (IBD) receiving anti-TNF treatment. Twenty-three consensus statements were initially drafted and then discussed by the committee members.

View Article and Find Full Text PDF
Article Synopsis
  • - The rise in anti-TNF therapy usage in Asian countries has led to increased concerns about tuberculosis (TB) risks in patients with inflammatory bowel disease (IBD), prompting experts to create guidelines for managing this issue.
  • - A committee from the Asian Organization for Crohn's and Colitis and the Asia Pacific Association of Gastroenterology drafted 23 consensus statements on TB risk assessment, detection, and management, which were then voted on by 211 IBD specialists across nine Asian countries.
  • - The finalized consensus emphasizes strategies for preparing patients for anti-TNF therapy, monitoring them during treatment, and managing any active TB infections that arise, ultimately aimed at improving health outcomes and reducing TB-related complications in this patient group.
View Article and Find Full Text PDF

Because anti-tumor necrosis factor (anti-TNF) therapy has become increasingly popular in many Asian countries, the risk of developing active tuberculosis (TB) among anti-TNF users may raise serious health problems in this region. Thus, the Asian Organization for Crohn's and Colitis and the Asian Pacific Association of Gastroenterology have developed a set of consensus statements about risk assessment, detection, and prevention of latent TB infection and management of active TB infection in patients with inflammatory bowel disease (IBD) receiving anti-TNF treatment. Twenty-three consensus statements were initially drafted and then discussed by the committee members.

View Article and Find Full Text PDF

We summarize the current status of endoscopic ultrasound (EUS) for the upper gastrointestinal (GI) tract solely in Asia, focusing on the staging of superficial cancers and the diagnosis of submucosal tumors (SMT), by analysis of questionnaire responses and a literature review. EUS for assessing the depth of superficial cancers of the upper GI tract is useful; however, evidence is lacking to support that EUS is superior to other modalities. The current status of EUS varies across different Asian countries, and standardization of the methods used both during the procedure and for depth subclassification is necessary to evaluate the diagnostic accuracy.

View Article and Find Full Text PDF